Outcomes after transcatheter aortic valve implantation with both edwards-SAPIEN and corevalve devices in a single center: The milan experience

Cosmo Godino, Francesco Maisano, Matteo Montorfano, Azeem Latib, Alaide Chieffo, Iassen Michev, Rasha Al-Lamee, Marta Bande, Marco Mussardo, Francesco Arioli, Alfonso Ielasi, Micaela Cioni, Maurizio Taramasso, Irina Arendar, Antonio Grimaldi, Pietro Spagnolo, Alberto Zangrillo, Giovanni La Canna, Ottavio Alfieri, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Objectives Our aim was to assess clinical outcome after transcatheter aortic valve implantation (TAVI) performed with the 2 commercially available valves with 3 delivery approaches selected in a stepwise fashion. Background Limited data exist on the results of a comprehensive TAVI program using different valves with transfemoral, transapical, and transaxillary approaches for treatment of severe aortic stenosis. Methods We report 30-day and 6-month outcomes of high-risk patients consecutively treated in a single center with either the Medtronic-CoreValve (MCV) (Medtronic, Minneapolis, Minnesota) or Edwards-SAPIEN valve (ESV) (Edwards Lifesciences, Irvine, California) delivered via the transfemoral or transaxillary approaches and ESV via the transapical approach. Results A total of 137 patients underwent TAVI: 107 via transfemoral (46 MCV and 61 ESV), 15 via transaxillary (12 MCV and 3 ESV), and 15 via transapical approach. After the transfemoral approach, the procedural success rate was 93.5%, and major vascular complication rate was 20.6%. No intra-procedural deaths occurred. The procedural success rates of transapical and transaxillary approaches were 86.6% and 93.3%, respectively. The 30-day mortality rate was 0.9% in transfemoral group and 13.3% in transapical, and no deaths occurred after transaxillary access. Cumulative death rate at 6 months was 12.2% in transfemoral, 26.6% in transapical, and 18.2% in transaxillary groups. At multivariable analysis, logistic European System for Cardiac Operative Risk Evaluation, body surface area, and history of cerebrovascular disease were significantly associated with an increased risk of major adverse cardiac and cerebrovascular events. Conclusions Routine TAVI using both MCV and ESV with a selection of approaches is feasible and allows treatment of a wide range of patients with good overall procedural success rates and 30-day and 6-month outcomes.

Original languageEnglish
Pages (from-to)1110-1121
Number of pages12
JournalJACC: Cardiovascular Interventions
Volume3
Issue number11
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Equipment and Supplies
Cerebrovascular Disorders
Mortality
Body Surface Area
Aortic Valve Stenosis
Blood Vessels
Transcatheter Aortic Valve Replacement
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Outcomes after transcatheter aortic valve implantation with both edwards-SAPIEN and corevalve devices in a single center : The milan experience. / Godino, Cosmo; Maisano, Francesco; Montorfano, Matteo; Latib, Azeem; Chieffo, Alaide; Michev, Iassen; Al-Lamee, Rasha; Bande, Marta; Mussardo, Marco; Arioli, Francesco; Ielasi, Alfonso; Cioni, Micaela; Taramasso, Maurizio; Arendar, Irina; Grimaldi, Antonio; Spagnolo, Pietro; Zangrillo, Alberto; La Canna, Giovanni; Alfieri, Ottavio; Colombo, Antonio.

In: JACC: Cardiovascular Interventions, Vol. 3, No. 11, 11.2010, p. 1110-1121.

Research output: Contribution to journalArticle

Godino, C, Maisano, F, Montorfano, M, Latib, A, Chieffo, A, Michev, I, Al-Lamee, R, Bande, M, Mussardo, M, Arioli, F, Ielasi, A, Cioni, M, Taramasso, M, Arendar, I, Grimaldi, A, Spagnolo, P, Zangrillo, A, La Canna, G, Alfieri, O & Colombo, A 2010, 'Outcomes after transcatheter aortic valve implantation with both edwards-SAPIEN and corevalve devices in a single center: The milan experience', JACC: Cardiovascular Interventions, vol. 3, no. 11, pp. 1110-1121. https://doi.org/10.1016/j.jcin.2010.09.012
Godino, Cosmo ; Maisano, Francesco ; Montorfano, Matteo ; Latib, Azeem ; Chieffo, Alaide ; Michev, Iassen ; Al-Lamee, Rasha ; Bande, Marta ; Mussardo, Marco ; Arioli, Francesco ; Ielasi, Alfonso ; Cioni, Micaela ; Taramasso, Maurizio ; Arendar, Irina ; Grimaldi, Antonio ; Spagnolo, Pietro ; Zangrillo, Alberto ; La Canna, Giovanni ; Alfieri, Ottavio ; Colombo, Antonio. / Outcomes after transcatheter aortic valve implantation with both edwards-SAPIEN and corevalve devices in a single center : The milan experience. In: JACC: Cardiovascular Interventions. 2010 ; Vol. 3, No. 11. pp. 1110-1121.
@article{048092bdf9ea4fb7b503b49f26be6da5,
title = "Outcomes after transcatheter aortic valve implantation with both edwards-SAPIEN and corevalve devices in a single center: The milan experience",
abstract = "Objectives Our aim was to assess clinical outcome after transcatheter aortic valve implantation (TAVI) performed with the 2 commercially available valves with 3 delivery approaches selected in a stepwise fashion. Background Limited data exist on the results of a comprehensive TAVI program using different valves with transfemoral, transapical, and transaxillary approaches for treatment of severe aortic stenosis. Methods We report 30-day and 6-month outcomes of high-risk patients consecutively treated in a single center with either the Medtronic-CoreValve (MCV) (Medtronic, Minneapolis, Minnesota) or Edwards-SAPIEN valve (ESV) (Edwards Lifesciences, Irvine, California) delivered via the transfemoral or transaxillary approaches and ESV via the transapical approach. Results A total of 137 patients underwent TAVI: 107 via transfemoral (46 MCV and 61 ESV), 15 via transaxillary (12 MCV and 3 ESV), and 15 via transapical approach. After the transfemoral approach, the procedural success rate was 93.5{\%}, and major vascular complication rate was 20.6{\%}. No intra-procedural deaths occurred. The procedural success rates of transapical and transaxillary approaches were 86.6{\%} and 93.3{\%}, respectively. The 30-day mortality rate was 0.9{\%} in transfemoral group and 13.3{\%} in transapical, and no deaths occurred after transaxillary access. Cumulative death rate at 6 months was 12.2{\%} in transfemoral, 26.6{\%} in transapical, and 18.2{\%} in transaxillary groups. At multivariable analysis, logistic European System for Cardiac Operative Risk Evaluation, body surface area, and history of cerebrovascular disease were significantly associated with an increased risk of major adverse cardiac and cerebrovascular events. Conclusions Routine TAVI using both MCV and ESV with a selection of approaches is feasible and allows treatment of a wide range of patients with good overall procedural success rates and 30-day and 6-month outcomes.",
author = "Cosmo Godino and Francesco Maisano and Matteo Montorfano and Azeem Latib and Alaide Chieffo and Iassen Michev and Rasha Al-Lamee and Marta Bande and Marco Mussardo and Francesco Arioli and Alfonso Ielasi and Micaela Cioni and Maurizio Taramasso and Irina Arendar and Antonio Grimaldi and Pietro Spagnolo and Alberto Zangrillo and {La Canna}, Giovanni and Ottavio Alfieri and Antonio Colombo",
year = "2010",
month = "11",
doi = "10.1016/j.jcin.2010.09.012",
language = "English",
volume = "3",
pages = "1110--1121",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Outcomes after transcatheter aortic valve implantation with both edwards-SAPIEN and corevalve devices in a single center

T2 - The milan experience

AU - Godino, Cosmo

AU - Maisano, Francesco

AU - Montorfano, Matteo

AU - Latib, Azeem

AU - Chieffo, Alaide

AU - Michev, Iassen

AU - Al-Lamee, Rasha

AU - Bande, Marta

AU - Mussardo, Marco

AU - Arioli, Francesco

AU - Ielasi, Alfonso

AU - Cioni, Micaela

AU - Taramasso, Maurizio

AU - Arendar, Irina

AU - Grimaldi, Antonio

AU - Spagnolo, Pietro

AU - Zangrillo, Alberto

AU - La Canna, Giovanni

AU - Alfieri, Ottavio

AU - Colombo, Antonio

PY - 2010/11

Y1 - 2010/11

N2 - Objectives Our aim was to assess clinical outcome after transcatheter aortic valve implantation (TAVI) performed with the 2 commercially available valves with 3 delivery approaches selected in a stepwise fashion. Background Limited data exist on the results of a comprehensive TAVI program using different valves with transfemoral, transapical, and transaxillary approaches for treatment of severe aortic stenosis. Methods We report 30-day and 6-month outcomes of high-risk patients consecutively treated in a single center with either the Medtronic-CoreValve (MCV) (Medtronic, Minneapolis, Minnesota) or Edwards-SAPIEN valve (ESV) (Edwards Lifesciences, Irvine, California) delivered via the transfemoral or transaxillary approaches and ESV via the transapical approach. Results A total of 137 patients underwent TAVI: 107 via transfemoral (46 MCV and 61 ESV), 15 via transaxillary (12 MCV and 3 ESV), and 15 via transapical approach. After the transfemoral approach, the procedural success rate was 93.5%, and major vascular complication rate was 20.6%. No intra-procedural deaths occurred. The procedural success rates of transapical and transaxillary approaches were 86.6% and 93.3%, respectively. The 30-day mortality rate was 0.9% in transfemoral group and 13.3% in transapical, and no deaths occurred after transaxillary access. Cumulative death rate at 6 months was 12.2% in transfemoral, 26.6% in transapical, and 18.2% in transaxillary groups. At multivariable analysis, logistic European System for Cardiac Operative Risk Evaluation, body surface area, and history of cerebrovascular disease were significantly associated with an increased risk of major adverse cardiac and cerebrovascular events. Conclusions Routine TAVI using both MCV and ESV with a selection of approaches is feasible and allows treatment of a wide range of patients with good overall procedural success rates and 30-day and 6-month outcomes.

AB - Objectives Our aim was to assess clinical outcome after transcatheter aortic valve implantation (TAVI) performed with the 2 commercially available valves with 3 delivery approaches selected in a stepwise fashion. Background Limited data exist on the results of a comprehensive TAVI program using different valves with transfemoral, transapical, and transaxillary approaches for treatment of severe aortic stenosis. Methods We report 30-day and 6-month outcomes of high-risk patients consecutively treated in a single center with either the Medtronic-CoreValve (MCV) (Medtronic, Minneapolis, Minnesota) or Edwards-SAPIEN valve (ESV) (Edwards Lifesciences, Irvine, California) delivered via the transfemoral or transaxillary approaches and ESV via the transapical approach. Results A total of 137 patients underwent TAVI: 107 via transfemoral (46 MCV and 61 ESV), 15 via transaxillary (12 MCV and 3 ESV), and 15 via transapical approach. After the transfemoral approach, the procedural success rate was 93.5%, and major vascular complication rate was 20.6%. No intra-procedural deaths occurred. The procedural success rates of transapical and transaxillary approaches were 86.6% and 93.3%, respectively. The 30-day mortality rate was 0.9% in transfemoral group and 13.3% in transapical, and no deaths occurred after transaxillary access. Cumulative death rate at 6 months was 12.2% in transfemoral, 26.6% in transapical, and 18.2% in transaxillary groups. At multivariable analysis, logistic European System for Cardiac Operative Risk Evaluation, body surface area, and history of cerebrovascular disease were significantly associated with an increased risk of major adverse cardiac and cerebrovascular events. Conclusions Routine TAVI using both MCV and ESV with a selection of approaches is feasible and allows treatment of a wide range of patients with good overall procedural success rates and 30-day and 6-month outcomes.

UR - http://www.scopus.com/inward/record.url?scp=78449247508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449247508&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2010.09.012

DO - 10.1016/j.jcin.2010.09.012

M3 - Article

C2 - 21087745

AN - SCOPUS:78449247508

VL - 3

SP - 1110

EP - 1121

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 11

ER -